InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
9
Disclosed sells
1
T+90 hit rate
50%
T+90 mean return
+11.8%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Hayden Michael R, Director. Insider active across 5 companies, notably Xenon Pharmaceuticals Inc.. Cumulatively, 20 disclosures have been published. Breakdown: 9 buys · 1 sell. Total volume traded: €4.7m. Activity tracked since 18 May 2021. The latest transaction was disclosed on 24 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Hayden Michael R
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations20 total
53,613 shares@ US$10.64Common SharesSEC:0001628280-26-058684:0
Canonical exit: 22 Nov 2026 (T+90)
46,387 shares@ US$10.370.013% mcap6.1% of flowCommon SharesSEC:0001628280-26-057007:0
Canonical exit: 10 Nov 2026 (T+90)
50,000 shares0Common SharesSEC:0001628280-26-056653:0
5,000 shares@ US$51.600.0028% mcap15.6% of flowCommon StockSEC:0000874015-26-000254:1
Canonical exit: 29 Oct 2026 (T+90)
15,000 shares@ US$53.380.0088% mcap48.8% of flowCommon StockSEC:0000874015-26-000254:0
Canonical exit: 28 Oct 2026 (T+90)
80,904 sharesCommon StockSEC:0001193125-25-259064:0
4,079 shares0Common StockSEC:0000874015-25-000157:0
15,000 shares@ US$31.8683.0% of flowCommon StockSEC:0000874015-25-000125:0
Canonical exit: 30 Jul 2025 (T+90)
2,500 shares@ US$36.198317.0% of flowCommon StockSEC:0000874015-24-000243:0
Canonical exit: 23 Mar 2025 (T+90)
20,000 shares@ US$4.910.7% of flowCommon SharesSEC:0001703057-23-000032:0
Canonical exit: 21 Dec 2023 (T+90)
30,000 shares@ US$5.901.3% of flowCommon SharesSEC:0001703057-23-000024:0
Canonical exit: 6 Nov 2023 (T+90)
1,777 shares0Common StockSEC:0000874015-23-000174:0
6,250 shares@ US$3.62100.0% of flowCommon StockSEC:0000950170-23-010969:0
Canonical exit: 28 Jun 2022 (T+90)
1,777 shares0Common StockSEC:0000874015-22-000165:0
5,333 shares0Common StockSEC:0000874015-22-000138:0
1,777 shares0Common StockSEC:0000874015-21-000162:0
270,000 shares@ US$17.7362.9% of flowCommon SharesSEC:0001209191-21-056163:0
5,333 shares0Common StockSEC:0000874015-21-000134:0
100,000 shares@ US$25.5033.2% of flowCommon SharesSEC:0000899243-21-025366:0
3,500 shares@ US$3.85100.0% of flowCommon SharesSEC:0001209191-21-034396:0
20 of 20 declarations
About Hayden Michael R
Hayden Michael R is a Director at Ionis Pharmaceuticals INC, AbCellera Biologics Inc., 89bio, Inc., and Xenon Pharmaceuticals Inc. Across 15 filings in total, the 15 sampled filings run from 2021-05-20 to 2025-10-30, with EUR 783680 in buys and EUR 2136263 in sells, and the most frequent transaction type is Option exercise.
